SHAREABLE PDF

Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension

Olivier Sitbon [1], Vincent Cottin [2], Matthieu Canuet [3], Pierre Clerson[4], Virginie Gressin[5], Loïc Perchenet[5], Laurent Bertoletti [6,7], Hélène Bouvaist[8], François Picard[9], Grégoire Prévot[10], Emmanuel Bergot[11] and Gérald Simonneau[1]

Affiliations: [1]APHP, National Reference Centre for Pulmonary Hypertension, Dept of Respiratory and Intensive Care Medicine, Bicêtre Hospital, University Paris-Sud – University Paris Saclay, INSERM UMR_S999, Le Kremlin-Bicêtre, France. [2]National Reference Centre for Rare Pulmonary Diseases, Dept of Pneumology, Louis Pradel Hospital, Claude Bernard University Lyon 1, UMR754, Lyon, France. [3]Dept of Pneumology, Nouvel Hôpital Civil, Strasbourg, France. [4]Soladis Clinical Studies, Biostatistics, Roubaix, France. [5]Actelion Pharmaceuticals Ltd, Allschwil, Switzerland. [6]Dept of Vascular Medicine and Therapeutics, Saint-Étienne University Hospital Centre, Saint-Étienne, France. [7]INSERM (National Institute of Health and Medical Research) U1059 and INSERM CIC1408, Saint-Étienne, France. [8]Cardiology Service, Michallon Hospital, Grenoble University Hospital Centre, Grenoble, France. [9]Heart Failure Unit and Pulmonary Hypertension Expert Centre, Bordeaux University Hospital, Bordeaux, France. [10]Dept of Pneumology, University Hospital, Toulouse, France. [11]Dept of Pneumology, University Hospital, Caen, France.

Correspondence: Olivier Sitbon, Service de Pneumologie, CHU Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin-Bicêtre, France. E-mail: olivier.sitbon@u-psud.fr

@ERSpublications
Initial combination therapy with macitentan and tadalafil is well tolerated and improves cardiopulmonary haemodynamics and functional capacity in newly diagnosed PAH patients https://bit.ly/3aWZagH

Cite this article as: Sitbon O, Cottin V, Canuet M, *et al*. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. *Eur Respir J* 2020; 56: 2000673 [https://doi.org/10.1183/13993003.00673-2020].

To the Editor:

Initial combination therapy plays a central role in managing pulmonary arterial hypertension (PAH) [1–4]. Patients with low- or intermediate-risk of 1-year mortality at diagnosis should be treated with initial combination therapy with an endothelin receptor antagonist (ERA) and phosphodiesterase type-5 inhibitor (PDE5i) [2–4]. Benefits of initial therapy with the ERA ambrisentan and PDE5i tadalafil were demonstrated in AMBITION [1]; prospective evidence for other treatment combinations within these drug classes is needed.